Skip to main content
. Author manuscript; available in PMC: 2023 Sep 12.
Published in final edited form as: Lancet Infect Dis. 2018 Mar 20;18(6):657–665. doi: 10.1016/S1473-3099(18)30113-0

Table 3:

Distribution of adverse events per study arm among all enrolled study participants

1 week group 2 week group 4 week group 4 week plusIPV group Total

Mild to moderate adverse events
Burn injury 0 0 0 1 1
Conjunctivitis 0 0 2 1 3
Diarrhoea 2 0 0 2 4
Vaccine-related fever 1 0 0 2 3
Respiratory infection 1 1 4 1 7
Oral candidiasis 0 1 0 1 2
Skin infection 1 0 2 1 4
Measles 0 1 0 0 1
Varicella 0 1 0 0 1
Serious adverse events
Pneumonia 1 0 1 0 2
Total 6 4 9 9 28

Data are n.